News

Antengene launches Phase III CLINCH-3 Trial of ATG-022 in advanced gastric cancer, building on 46.7% response rates from Phase...

Lavengratinib achondroplasia trial shows 100% responder rate in lowest dose cohort with 2.4 cm/year growth improvement and clean safety...

Velocity Clinical Research appoints Justin Starzyk as CEO to lead its 70+ research sites across the U.S. and Europe.

Teva study reveals healthcare providers prioritize tolerability and dosing convenience over efficacy when treating tardive dyskinesia in older patients.

TEV-749 olanzapine LAI achieved 80% clinical stabilization in schizophrenia patients during the SOLARIS Phase 3 trial, with durability sustained...

CHMP recommends Ocrevus pediatric relapsing MS approval for children aged 10+, advancing toward European Commission authorization within two months.

FDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancer, doubling progression-free survival in Phase 3 trials.

Certara launches External Data Accelerator to catch vendor data conformance issues before submission, addressing 70% of clinical study data...

Boehringer Ingelheim's PED Essentials teaches patient organizations to collect and structure patient experience data for regulatory submissions and advocacy.

New analysis suggests nonmelanoma skin cancer cases are 42% higher than official counts, with annual patient numbers reaching 4.7...